Corporate ProfileWe are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.
Mar172021March 17, 2021 at 1:10 PM EDTMarch 17, 2021
1:10 PM EDT
Feb252021February 25, 2021 at 5:00 PM ESTFebruary 25, 2021
5:00 PM EST